Get the Stockscreener App
4.78
2.65%
-0.13
After Hours:
4.72
-0.06
-1.26%
Evaxion A S Adr stock is traded at $4.78, with a volume of 97,611.
It is down -2.65% in the last 24 hours and down -19.46% over the past month.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
See More
Previous Close:
$4.91
Open:
$4.85
24h Volume:
97,611
Relative Volume:
0.25
Market Cap:
$39.87M
Revenue:
-
Net Income/Loss:
$-11.46M
P/E Ratio:
-0.3414
EPS:
-14
Net Cash Flow:
$-24.56M
1W Performance:
+1.06%
1M Performance:
-19.46%
6M Performance:
+95.10%
1Y Performance:
-0.20%
1-Day Range:
$4.76
$5.0164
1-Week Range:
$4.70
$5.22
52-Week Range:
$1.20
$12.15
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
4.78 | 40.95M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Benzinga
European Firms Make Gains On US Markets As ADR Index Rises - Finimize
European ADRs Edge Higher Despite Mixed Stock Moves - Finimize
Evaxion Biotech Reports Strong Q3 2025 Results - MSN
Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Price Target at $12.33 - Defense World
European ADRs Edge Up With Gains Led By Evaxion - Finimize
Evaxion Biotech’s Earnings Call Highlights Strategic Growth - TipRanks
Analysts Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $12.33 - Defense World
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
European ADRs Barely Budge While Gainers And Losers Trade Places - Finimize
Evaxion A/S (NASDAQ:EVAX) Given Buy Rating at HC Wainwright - Defense World
European ADRs Edge Higher As Healthcare Leads Gains - Finimize
Take off with Evaxion A/S ADR (EVAX): Get ready for trading - setenews.com
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Sees Large Growth in Short Interest - Defense World
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough - ts2.tech
Nothing is Better Than Connexa Sports Technologies Inc (YYAI) stock at the moment - Setenews
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Evaxion Biotech price target raised to $16 from $14 at H.C. Wainwright - MSN
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Taking on analysts’ expectations and winning: Aditxt Inc (ADTX) - Setenews
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):